Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.22 +0.42%

+$0.02 today

Market cap
$167.38M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 2.04M

Average 0.45M

IVA EBITDA Margin

EBITDA as a percentage of revenue.

Inventiva S.A.NASDAQ: IVA

EBITDA Margin · Q4 FY2025 · quarter ended Dec 2025

EBITDA Margin narrows to -270065.3%

EBITDA Margin was -270065.3% in Q4 FY2025, down 268290.7 pp from a year earlier. Over 3 fiscal years it narrowed by 2396.4 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 9 analysts of -3166.3% for the fiscal year ending Dec 2026, down from -2858.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-270065.3%— QoQ
Last fiscal yearDec 2025
-2858.6%-1048.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-268290.7 pp——
1 year-1048.1 pp-307.7 pp+740.4 pp
3 years-2396.4 pp+2830.2 pp+5226.6 pp
5 years+2882.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2858.6%
Year-over-year change
-1048.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IVA compares with its peers on the latest reported figures

  • IVA's FY2025 EBITDA Margin of -2858.6% is the 5th highest of the 8 companies compared; the peer median is -999.5%.
  • Its year-over-year change of -1048.1 pp is the 5th highest of 7, against a peer median of +156.1 pp.
  • Over three fiscal years its change of -2396.4 pp compares with a peer median of -608.7 pp.
IVA Competitors Peer median
EBITDA Margin for IVA and competitors
Company Period LTM level YoY 3-year change
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-67.3% +67.9 pp+30.0 pp
IVVDInvivyd, Inc.LTM Mar 2026-135.5% +244.4 pp—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-161.1% +2125.8 pp+792.0 pp
CRBUCaribou Biosciences, Inc.LTM Mar 2026-999.5% +475.3 pp-608.7 pp
IVAInventiva S.A.FY2025-2858.6% -1048.1 pp-2396.4 pp
RNACCartesian Therapeutics, Inc.LTM Mar 2026-8932.3% -8827.3 pp-4917.5 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-33540.9% ——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-142957.6% -159600.9 pp-131573.1 pp
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
Peer median (excluding IVA) -999.5%+156.1 pp-608.7 pp

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.19M12.18M17.48M9.2M4.48M
Cost of Revenue1.02M995K(23K)3.88M2.8M
Gross Profit4.19M17.06M17.5M9.2M1.51M
Gross Margin100.0%140.1%100.1%100.0%33.7%
Research & Development48.45M60.47M110.01M90.88M83.61M
Selling, General & Admin11.52M15.5M15.61M17.1M53.89M
Operating Expenses56.31M74.17M120.19M106.76M137.37M
Depreciation & Amortization858K870K2.6M5.2M2.8M
EBITDA(52.76M)(56.29M)(102.04M)(166.53M)(128.15M)
EBITDA Margin-1258.0%-462.2%-583.9%-1810.4%-2858.6%
Operating Income(52.11M)(57.11M)(102.71M)(97.56M)(130.95M)
Operating Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%
Interest Income57K390K945K1.14M2.83M
Interest Expense138K707K5.18M12.18M32.3M
Other Income / Expenses2.84M2.82M(7.11M)(86.34M)(211.38M)
Income Before Tax(49.27M)(54.29M)(109.82M)(183.9M)(342.33M)
Pre-Tax Margin-1174.8%-445.8%-628.4%-1999.4%-7636.1%
Income Tax Expense364K(20K)607K313K22K
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Net Margin-1183.5%-445.6%-631.8%-2002.7%-7587.8%
EPS (Basic)(1.27)(1.31)(2.43)(3.54)(1.82)
EPS (Diluted)(1.27)(1.31)(2.43)(3.54)(1.82)
Weighted Avg Shares39.17M41.45M45.35M51.98M186.8M
Weighted Avg Shares (Diluted)39.17M41.45M45.35M51.98M186.8M

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.